Therapeutics , Targets , and Chemical Biology PIK 3 CA Mutation H 1047 R Is Associated with Response to PI 3 K / AKT / mTORSignalingPathway Inhibitors in Early-Phase Clinical Trials

PIK3CAmutations may predict response to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype has not been investigated. Patients with diverse cancers referred to the Clinical Center for Targeted Therapy were analyzed for PIK3CA and, if possible, KRAS mutations. Patients with PIK3CA mutations were treated… CONTINUE READING